Publikationen

2015

 

• Comparison of three noninvasive methods for hemoglobin screening of blood donors.

       Ardin S, Störmer M, Radojska S, Oustianskaia L, Hahn M, Gathof BS.

       Transfusion 2015; 55:379-87 doi: 10.1111/trf.12819. 0

• Validation of microbiological control of stem cell preparations according to German regulators recommendations – Boon and Bane for the manufacturer.

      Störmer M, Radojska S, Hos NJ, Gathof BS.

      Vox Sang. 2015 Apr;108(3):314-7. doi: 10.1111/vox.12222.

 

 2014

• Emergency medical equipment on board German airliners.

     Hinkelbein J, Neuhaus C, Wetsch WA, Spelten O, Picker S, Böttiger B.W, Gathof BS.

       J Travel Med. 2014 Sep-Oct;21(5):318-23. doi: 10.1111/jtm.12138.

 

• Besonderheiten der Herstellung von autologen Serum-Augentropfen - 2 Years of Experience in Manufacturing Autologous Serum Eye Drops.

     Petrescu V, Radojska S, Tahmaz V, Steven P, Störmer M, Cursiefen C,  Gathof BS.

     Transfusionsmedizin. 2014; 4:139–142.

 

• Bacterial safety of cell-based therapeutic preparations, focusing on haematopoietic progenitor cells.

      Störmer M, Wood EM, Schurig U, Karo O, Spreitzer I, McDonald CP, Montag T.

      Vox Sang. 2014; 106:285-96. (Review)

 

• Diagnostic methods for platelet bacteria screening: current status and developments.

      Störmer M, Vollmer T.

      Transfus Med Hemother. 2014; 41:19-27.

 

• The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines.

      Benjamin RJ, McDonald C, Ramirez-Arcos S, DeKorte D, Jacobs M, Heaton   A, Wood E, Stoermer M, Spindler-Raffel E, Gabel C, Szczepiorkowski Z,      Marschner S. (ISBT Transfusion Transmitted Infectious Disease Bacterial Workgroup).

     Transfus Med Rev. 2014; 28:61-71. (Review)

2013

 

• No disadvantage of pathogen-reduced platelets?

      Gathof BS.

      Dtsch Med Wochenschr. 2013 Oct;138(42):2132. doi: 10.1055/s-0032-1329158.

 

• Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility.

      Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L,   Vonk  MC,  Carreira PE, Vargas S, Román-Ivorra JA, González-Gay MA, Tolosa C,   López-Longo FJ, Espinosa G, Vicente EF, Hesselstrand R, Riemekasten G, Witte T, Distler JH, Voskuyl AE, Schuerwegh AJ, Shiels PG, Nordin A, Padyukov L, Hoffmann-Vold AM, Scorza R, Lunardi C, Airo P, van Laar JM, Hunzelmann N, Gathof BS, Kreuter A, Herrick A, Worthington J, Denton CP, Zhou X, Arnett FC, Fonseca C, Koeleman BP, Assasi S, Radstake TR, Mayes MD, Martín J; Spanish Scleroderma Group.

     Ann Rheum Dis. 2013 Jul;72(7):1233-8. doi: 10.1136/annrheumdis-2012-202357.

 

2012

 

• ABO-incompatible kidney transplantation using regenerative selective immunoglobulin adsorption.

      Teschner S, Stippel D, Grunenberg R, Beck B, Wahba R, Gathof B,     Benzing T, Burst V.

      J Clin Apher. 2012;27(2):51-60. doi: 10.1002/jca.21201.

 

• Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.

       Tauszig ME, Picker SM, Gathof BS.

       Transfus Apher Sci. 2012 Feb;46(1):33-7. doi: 10.1016/j.transci.2011.10.025.

 

• Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.

       Picker SM, Tauszig ME, Gathof BS.

       Transfusion. 2012 Mar;52(3):510-6. doi: 10.1111/j.1537-2995.2011.03323.x.

 

2011

 

• Blood-based gene expression signatures in non-small cell lung cancer.

      Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S,   Maisel D, Ansén S, Hahn M, Beyer M, Thomas RK, Gathof B, Mauch C, Delank KS, Engel-Riedel W, Wichmann HE, Stoelben E, Schultze JL, Wolf J.

     Clin Cancer Res. 2011 May 15;17(10):3360-7. doi: 10.1158/1078-0432.CCR-10-0533.

  

• Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions.

      Ambruso DR, Thurman G, Tran K, Marschner S, Gathof B, Janetzko K,   Goodrich RP.

     Transfusion. 2011 Jun;51(6):1220-7. doi: 10.1111/j.1537-2995.2010.02983.x.

 

2010

• Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction.

 

Picker SM, Oustianskaia L, Schneider V, Gathof BS.

      Transfus Med Hemother. 2010 Feb;37(1):7-12.

 

• Bead array-based microrna expression profiling of peripheral blood and the impact of different RNA isolation approaches.

       Gaarz A, Debey-Pascher S, Classen S, Eggle D, Gathof B, Chen J, Fan JB,  Voss T, Schultze JL, Staratschek-Jox A.

      J Mol Diagn. 2010 May;12(3):335-44. doi: 10.2353/jmoldx.2010.090116.

 

2009

 

• Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies.

      Picker SM, Schneider V, Oustianskaia L, Gathof BS.

      Transfusion. 2009 Nov;49(11):2311-8. doi: 10.1111/j.1537-2995.2009.02316.x.

 

• Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.

       Picker SM, Oustianskaia L, Schneider V, Gathof BS.

       Vox Sang. 2009 Jul;97(1):26-33. doi: 10.1111/j.1423-0410.2009.01176.x.

 

• Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.

       Picker SM, Steisel A, Gathof BS.

       Transfus Apher Sci. 2009 Apr;40(2):79-85. doi: 10.1016/j.transci.2009.01.013.

 

• Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.

      Picker SM, Schneider V, Gathof BS.

      Transfusion. 2009 Jun;49(6):1224-32. doi: 10.1111/j.1537-2995.2009.02092.x.

 

• Leukocyte depletion in allogeneic blood transfusion does not change the negative influence on survival following transthoracic resection for esophageal cancer.

       Ling FC, Hoelscher AH, Vallböhmer D, Schmidt D, Picker S,  Gathof  B S,       Bollschweiler E, Schneider PM.

     J Gastrointest Surg. 2009 Apr;13(4):581-6. doi: 10.1007/s11605-008-0787-1.

 

• Evaluation of White Blood Cell- and Platelet-Derived Cytokine Accumulation in MIRASOL-PRT-Treated Platelets.

      Picker SM, Steisel A, Gathof BS.

      Transfus Med Hemother. 2009;36(2):114-120.

 

2008

 

• Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.

       Picker SM, Steisel A, Gathof BS.

       Transfusion. 2008 Aug;48(8):1685-92. doi: 10.1111/j.1537-2995.2008.01778.x.

  

• Effect of blood donation on well-being of blood donors.

      Hinrichs A, Picker SM, Schneider A, Lefering R, Neugebauer EA, Gathof BS.

      Transfus Med. 2008 Feb;18(1):40-8. doi: 10.1111/j.1365-3148.2007.00805.x.

 

• Evaluation of Four Bedside Test Systems for Card Performance, Handling and Safety.

       Giebel F, Picker SM, Gathof BS.

      Transfus Med Hemother. 2008;35(1):33-36.

 

2007

•  In vitro quality of red blood cells (RBCs) collected by multicomponent apheresis  compared to manually collected RBCs during 49 days of storage.

       Picker SM, Radojska SM, Gathof BS.

       Transfusion. 2007 Apr;47(4):687-96.

 

• Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome.

       Picker SM, Kaleta T, Hekmat K, Kampe S, Gathof BS.

       Eur J Anaesthesiol. 2007 Apr;24(4):332-9.

 

2006

 

• Prospective evaluation of double RBC collection using three different apheresis systems.

      Picker SM, Radojska SM, Gathof BS.

      Transfus Apher Sci. 2006 Dec;35(3):197-205.

 

• Prospective comparison of high-dose plateletpheresis with the latest apheresis systems on the same donors.

      Picker SM, Radojska SM, Gathof BS.

      Transfusion. 2006 Sep;46(9):1601-8.

 

• Evaluation of concurrent collection of in-line filtered platelets and packed red blood cells by multicomponent apheresis with three last-generation apparatuses.

      Picker SM, Radojska SM, Gathof BS.

      Vox Sang. 2006 Jul;91(1):47-55.

 

2004

• Leucodepletion leads to component-like storage stability of whole blood--suggesting its homologous use?

       Picker SM, Stürner SS, Oustianskaja L, Gathof BS.

       Vox Sang. 2004 Oct;87(3):173-81.

 

• [Heparin induced thrombocytopenia. A frequently unrecognised complication after major orthopedic surgery].

      Picker SM, Gathof BS.

      Orthopade. 2004 Nov;33(11):1300-8. Review. German.

 

• Pathophysiology, epidemiology, diagnosis and treatment of heparin-induced thrombocytopenia (HIT).

      Picker SM, Gathof BS.

      Eur J Med Res. 2004 Apr 30;9(4):180-5. Review.

 

• Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization.

      Picker SM, Speer R, Gathof BS.

      Transfus Med. 2004 Jun;14(3):217-23.

 

•  Epidemiology, etiology and diagnosis of venous thrombosis.

       Gathof BS, Picker SM, Rojo J.

       Eur J Med Res. 2004 Mar 30;9(3):95-103. Review.

 

• Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types.

      Debey S, Schoenbeck U, Hellmich M, Gathof BS, Pillai R, Zander T, Schultze JL.

      Pharmacogenomics J. 2004;4(3):193-207.

 

• Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation.

      Picker SM, Speer R, Gathof BS.

      Transfusion. 2004 Mar;44(3):320-9.

 

• Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.

      Gresser U, Gathof BS.

      Eur J Med Res. 2004 Jan 26;9(1):1-17. Review.

 

2003

• Desflurane inhibits platelet function in vitro similar to halothane.

       Berlet T, Krah A, Börner U, Gathof BS.

       Eur J Anaesthesiol. 2003 Nov;20(11):878-83.

 

• Function, expression and localization of annexin A7 in platelets and red blood cells: insights derived from an annexin A7 mutant mouse.

       Herr C, Clemen CS, Lehnert G, Kutschkow R, Picker SM, Gathof BS,    Zamparelli C, Schleicher M, Noegel AA.

       BMC Biochem. 2003 Aug 19;4:8.

 

• Re-operation for complicated secondary peritonitis - how to identify patients at risk for persistent sepsis.

       Holzheimer RG, Gathof B.

       Eur J Med Res. 2003 Mar 27;8(3):125-34.

 

2002

 

• Biochemical and molecular study of mentally retarded patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase.

      Micheli V, Gathof BS, Rocchigiani M, Jacomelli G, Sestini S, Peruzzi L,   Notarantonio L, Cerboni B, Hayek G, Pompucci G.

      Biochim Biophys Acta. 2002 May 21;1587(1):45-52.

 

• Human error: the persisting risk of blood transfusion: a report of five cases.

      Krombach J, Kampe S, Gathof BS, Diefenbach C, Kasper SM.

      Anesth Analg. 2002 Jan;94(1):154-6, table of contents.

 

2000

• Evaluation of a nucleic acid-based cross-linking assay to screen for hereditary hemochromatosis in healthy blood donors.

      Wylenzek C, Engelmann M, Holten D, Van Atta R, Wood M, Gathof B.

      Clin Chem. 2000 Nov;46(11):1853-5. No abstract available.